Lisanti Capital Growth’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Lisanti Capital Growth’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-75,947	Closed	-$9.01M	–	152
2022 Q1	$9.01M	Sell	75,947 -8,223	-10%	-$1.03M	1.01%	37
2021 Q4	$11.6M	Sell	84,170 -1,110	-1%	-$141K	1.68%	9
2021 Q3	$11.8M	Buy	+85,280	New	+$10.6M	1.75%	9
2020 Q4	–	Sell	-93,498	Closed	-$6.08M	–	158
2020 Q3	$6.08M	Buy	93,498 +38,443	+70%	+$2.52M	1.13%	44
2020 Q2	$4.03M	Buy	+55,055	New	+$2.93M	0.82%	62
2020 Q1	–	Sell	-14,990	Closed	-$816K	–	160
2019 Q4	$816K	Buy	+14,990	New	+$742K	0.22%	104

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lisanti Capital Growth's BHVN Position: Q2 2022 in Review

Lisanti Capital Growth sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 75,947 shares — an estimated $9.01M sold.

Lisanti Capital Growth first reported a position in BHVN in Q4 2019 and held it in 6 quarters. The position peaked at $11.8M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Lisanti Capital Growth reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Lisanti Capital Growth sold 75,947 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $9.01M.
Lisanti Capital Growth first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 6 quarters.
Lisanti Capital Growth's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $11.8M in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Lisanti Capital Growth's 13F filing for Q2 2022, filed 3 Aug 2022.